Skip to main content
. 2016 Sep 12;24(5-6):161–165. doi: 10.1177/2040206616665971

Figure 1.

Figure 1.

Effect of DAS181 treatment of HEp-2 cells on hMPV (strains A2, B1, and B2) infectivity. (a) Hep-2 cells were treated with 10 µg/ml DAS181 or DAS185 for 2 h prior to inoculation with hMPV. Untreated control cells were treated with EDB–BSA buffer before inoculation with virus. Infectivity was assessed by ELISA 48 h postinoculation using MAb against hMPV matrix protein. Results shown are mean ± SD for triplicate wells of a representative experiment performed twice. OD 490 nm, optical density at 490 nm. (b) Dose-dependent inhibition of hMPV strain V32748 (B1) infectivity by DAS181. Experiments were performed as described above except Hep-2 cells were treated with varying concentrations of DAS181. Results are expressed as percent inhibition of infection relative to that of untreated cells.